Unlock stock picks and a broker-level newsfeed that powers Wall Street.
NasdaqGS - Nasdaq Real Time Price USD

Moderna, Inc. (MRNA)

Compare
25.64
+0.53
+(2.11%)
At close: 4:00:02 PM EDT
25.75
+0.11
+(0.41%)
After hours: 6:34:03 PM EDT
Loading Chart for MRNA
  • Previous Close 25.11
  • Open 24.05
  • Bid 24.17 x 100
  • Ask 26.82 x 100
  • Day's Range 23.15 - 26.51
  • 52 Week Range 23.15 - 170.47
  • Volume 13,231,800
  • Avg. Volume 11,818,013
  • Market Cap (intraday) 9.913B
  • Beta (5Y Monthly) 2.23
  • PE Ratio (TTM) --
  • EPS (TTM) -9.28
  • Earnings Date Apr 30, 2025 - May 5, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 52.35

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Generation Bio Co.; immatics N.V.; Life Edit Therapeutics; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

www.modernatx.com

5,800

Full Time Employees

December 31

Fiscal Year Ends

Recent News: MRNA

View More

Performance Overview: MRNA

Trailing total returns as of 4/7/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

MRNA
38.34%
S&P 500 (^GSPC)
13.93%

1-Year Return

MRNA
75.08%
S&P 500 (^GSPC)
2.73%

3-Year Return

MRNA
83.87%
S&P 500 (^GSPC)
12.49%

5-Year Return

MRNA
19.93%
S&P 500 (^GSPC)
90.35%

Compare To: MRNA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: MRNA

View More

Valuation Measures

As of 4/4/2025
  • Market Cap

    9.71B

  • Enterprise Value

    3.43B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.01

  • Price/Book (mrq)

    0.89

  • Enterprise Value/Revenue

    1.07

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -110.04%

  • Return on Assets (ttm)

    -15.14%

  • Return on Equity (ttm)

    -28.77%

  • Revenue (ttm)

    3.24B

  • Net Income Avi to Common (ttm)

    -3.56B

  • Diluted EPS (ttm)

    -9.28

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    7.02B

  • Total Debt/Equity (mrq)

    6.85%

  • Levered Free Cash Flow (ttm)

    -3.09B

Research Analysis: MRNA

View More

People Also Watch